Preclinical Landscape in Cancer Research

Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com)Yashwant Pathak is a Professor at Taneja College of Pharmacy at the University of South Florida, FL, United States. His area of research is nanotechnology, drug delivery systems, and nutraceuticals. He is also an Ad junct Professor at the Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.

• 1. Liver cancer: current status of preclinical research2. Pancreatic cancer: current status of preclinical research3. Heart cancer: current status of preclinical research4. Bone cancer: current status of preclinical research5. Spleen cancer: current status of preclinical research6. ENT cancer: current status of preclinical research7. Brain/CSN cancer: current status of preclinical research8. Skin cancer: current status of preclinical research9. Lung cancer: current status of preclinical research10. Thorax cancer: current status of preclinical research11. Thyroid cancer: current status of preclinical research12. Kidney-adrenal cancer: current status of preclinical research13. Urinary tracker cancer: current status of preclinical research14. Breast cancer: current status of preclinical research15. Blood cancer: current status of preclinical research16. Prostate cancer: current status of preclinical research17. Gynecologic cancer: current status of preclinical research18. Stomach and intestinal cancer: current status of preclinical research19. Plura and peritoneum cancer: current status of preclinical research20. Ocular cancer: current status of preclinical research21. Oral cancer: current status of preclinical research22. Growth Inhibitory Effects of Unsaturated Linoleinic Acid with Conjugated Double Bonds for Colon Cancer Prevention